# CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2020

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2020-05-06
- Accepted by EDGAR: May 6, 2020, 06:39 ET
- Period: 2020-03-31
- Accession: 0000064803-20-000015
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000006480320000015/a0331202010-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000006480320000015/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-01-01 to 2020-03-31 | $66.75bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2020-01-01 to 2020-03-31 | $40.35bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | $3.46bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-01-01 to 2020-03-31 | $733.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-01-01 to 2020-03-31 | $767.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | $2.01bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-01-01 to 2020-03-31 | $1.53 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-01-01 to 2020-03-31 | $1.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-01-01 to 2020-03-31 | 1,312,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2020-01-01 to 2020-03-31 | $3.31bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2020-01-01 to 2020-03-31 | $742.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2020-01-01 to 2020-03-31 | $652.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2020-03-31 | $10.08bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-03-31 | $58.96bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $230.64bn | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $59.56bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-03-31 | $165.16bn | us-gaap:Liabilities |
| Long-term debt | at 2020-03-31 | $65.73bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2020-03-31 | $5.83bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2020-03-31 | $255.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2020-03-31 | $65.14bn | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/64803/000006480320000015/a0331202010-q.htm

Filed May 6, 2020.
Source: SEC EDGAR, the filing index for accession 0000064803-20-000015. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
